摘要
巨细胞病毒性视网膜炎是获得性免疫缺陷综合征晚期最常见、最严重的眼部机会性感染,是导致患者视力丧失的最主要原因.继更昔洛韦、膦甲酸在临床广泛应用后,缬更昔洛韦、西多福韦及福米韦生也已经获得美国药品与食品管理局批准,先后应用于眼科临床,取得了一定的治疗效果.目前,马立巴韦、MSL-109单克隆抗体、Cyclopropavir及BAY 38-4766 正在进行Ⅰ期、Ⅱ期或Ⅲ期临床试验,可望给临床治疗带来新的希望.
Cytomegalovirus retinitis has been the most common opportunistic infection and leading cause of visual loss in AIDS patients. There are five drugs approved by the Food and Drug Administration in the USA for the treatment of cytomegalovirus retinitis: ganeiclovir, foscarnet/phosphonoformic acid,valganciclovir, eidofovir and formivirsen. Progress has been made in the treatment of cytomegalovirus retinitis. Nowadays, maribavir, monoclonal antibody MSL-109, cyclopropavir and BAY 38-4766 are entering clinical trials. This review summarizes present status and advances in pharmacotherapy for cytomegalovirus retinitis in AIDS.
出处
《中华眼科杂志》
CAS
CSCD
北大核心
2010年第12期1148-1152,共5页
Chinese Journal of Ophthalmology